Adjuvant treatment for EGFR mutant non-small cell lung cancer based on MRD status

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of postoperative adjuvant therapy using EGFR-TKIs in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (NSCLC) based on their minimal residual disease (MRD) status. Participants will undergo MRD assessments shortly after surgery and will be categorized into MRD positive or negative groups. Those in the MRD positive group will receive icotinib, with treatment adjustments based on their MRD status, while the MRD negative group will be monitored and treated with osimertinib if their MRD status changes. The primary endpoints focus on disease-free survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent provided.
2. Males or females aged ≥18 years, \< 80 years.
3. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
4. Target population is completely resected pathological stage IB-IIIB NSCLC with EGFR exon 19 deletions, L861Q mutation, G719X mutation and exon 21 L858R activating mutation.
5. Patients who have recovered from R0 resection including lobectomy, sleeve surgery and pneumonectomy.
6. ECOG performance status 0-1.
7. Life expectancy ≥12 weeks.
8. Adequate hematological function: Absolute neutrophil count (ANC) ≥1.8 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level).
9. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.
10. Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min.
11. Female subjects should not be pregnant or breast-feeding.

Exclusion Criteria:

1. Known severe hypersensitivity to icotinib, osimertinib or any of the excipients of this product.
2. Inability to comply with protocol or study procedures.
3. A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
4. A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.
5. Interstitial pneumonia.
6. Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, icotinib, cetuximab, trastuzumab).
7. Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy).
8. Patients with prior radiotherapy to primary lesion or lymph nodes.
9. History of another malignancy in the last 5 years with the exception of the following: Other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.
10. Any unstable systemic disease (including active infection, uncontrolled hypertension (systolic pressure \> 160mmHg, diastolic pressure \> 100mmHg), unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
11. Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.
12. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.
13. Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over) Patients who harboring exon 20 T790M mutation, EGFR 20 insertions, ALK fusion, BRAF V600E mutation, MET amplification and KRAS mutation.

Where it's running

• Guangdong Provincial People's Hospital
  Guanzhou, China Recruiting
• Beijing Friendship Hospital, Capital Medical University
  Beijing, China Not yet recruiting
• Chongqing University Three Gorges Hospital
  Chongqing, China Not yet recruiting
• The First People's Hospital of Foshan
  Foshan, China Not yet recruiting
• Fujian Medical University Union Hospital
  Fuzhou, China Not yet recruiting
• Affiliated Cancer Hospital of Guangzhou Medical University
  Guangzhou, China Not yet recruiting

Study contacts

• Study coordinator: Yi-Long Wu, MD
• Email: syylwu@live.cn
• Phone: 020-83827812

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How well minimal residual disease is cleared in AL amyloidosis after first-line Dara-BorCyD

  This study tests whether achieving very good partial or complete marrow responses with Dara-BorCyD and planned stem cell transplant helps AL amyloidosis patients, by looking at minimal residual disease after treatment.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07215494

• Adaptive adjuvant sintilimab treatment guided by MRD for resected Stage II–IIIB NSCLC

  This trial tests whether using postoperative blood MRD tests to guide adjuvant sintilimab helps people with resected Stage II–IIIB NSCLC who did not achieve a complete response after neoadjuvant chemo‑immunotherapy.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 1 other locations · NCT07120698

• Observing MRD's role in local treatment for oligometastatic breast cancer

  This study is trying to see if measuring minimal residual disease (MRD) can help doctors figure out which patients with oligometastatic breast cancer will do better after local treatment.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT06918262

• MRD-guided treatment for high-risk newly diagnosed multiple myeloma

  This treatment will test whether combining daratumumab, carfilzomib, lenalidomide and dexamethasone, with or without autologous stem‑cell transplant and MRD‑guided maintenance, can keep high‑risk newly diagnosed multiple myeloma patients free of measurable disease for one year.

  Recruiting Phase 4 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06409702

• Adaptive treatment for acute myeloid leukemia based on early results

  This study is testing a new treatment plan for people with untreated acute myeloid leukemia to see if adding a drug called selinexor helps those who still have cancer after two weeks of initial therapy.

  Recruiting Phase 2 Shanghai Tong Ren Hospital · Shanghai and 3 other locations · NCT05736978

• CD19 CAR-T versus donor lymphocyte infusion for clearing MRD after allogeneic stem cell transplant in Ph-negative B-ALL

  This trial tests whether a single infusion of autologous CD19 CAR-T cells or chemotherapy plus donor lymphocyte infusion better clears minimal residual disease in patients aged 3–79 with Ph-negative B‑cell ALL after allogeneic stem cell transplant.

  Recruiting Phase 3 Peking University People's Hospital · Beijing, China · NCT07441291

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.